225 related articles for article (PubMed ID: 16827720)
1. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
[TBL] [Abstract][Full Text] [Related]
2. Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.
Otsuka T; Kasai H; Yamaguchi K; Nishihara T
J Dent; 2005 Oct; 33(9):749-55. PubMed ID: 16199283
[TBL] [Abstract][Full Text] [Related]
3. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
4. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
[TBL] [Abstract][Full Text] [Related]
6. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
[TBL] [Abstract][Full Text] [Related]
7. c-myc is required for osteoclast differentiation.
Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
9. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
10. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
[TBL] [Abstract][Full Text] [Related]
12. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
13. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
Oikawa A; Kobayashi M; Okamatsu Y; Shinki T; Kamijo R; Yamamoto M; Hasegawa K
J Periodontal Res; 2007 Aug; 42(4):367-76. PubMed ID: 17559635
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts.
Galli C; Macaluso GM; Guizzardi S; Vescovini R; Passeri M; Passeri G
J Periodontol; 2006 Jul; 77(7):1223-8. PubMed ID: 16805686
[TBL] [Abstract][Full Text] [Related]
17. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways.
Takami M; Cho ES; Lee SY; Kamijo R; Yim M
FEBS Lett; 2005 Jan; 579(3):832-8. PubMed ID: 15670856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
